Physician profile
Edward Duffy
NPI 1568516383
$1,040.69
in general payments reported to CMS, 2019-2025
21 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2023: $21.87 · 2024: $372 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $171.90 | 2024-2025 | |
| Theragenics Corporation | $115.57 | 2019 | |
| Novocure INC. | $115.32 | 2024-2025 | Optune Lua (Novottf-200t) |
| Medtronic USA, INC. | $77.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.00 | 2024-2025 | Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $55.74 | 2024-2025 | Tagrisso |
| Jazz Pharmaceuticals INC. | $47.75 | 2025 | |
| Genmab U.S., INC. | $44.61 | 2024-2025 | Tivdak, Epkinly |
| Adc Therapeutics America, INC. | $42.82 | 2024-2025 | |
| Sobi, INC | $40.66 | 2025 | |
| Genentech USA, INC. | $39.65 | 2025 | Itovebi, Tecentriq |
| Merck Sharp & Dohme LLC | $34.52 | 2024 | Keytruda |
| Stemline Therapeutics INC. | $25.74 | 2025 | Orserdu |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $23.61 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $22.59 | 2025 | Ayvakit |
| Siemens Medical Solutions USA, INC. | $21.87 | 2023 | Varian Identify |
| Genzyme Corporation | $19.22 | 2025 | |
| Beigene USA, INC. | $17.82 | 2024 | Brukinsa |
| Springworks Therapeutics, INC. | $15.64 | 2024 | Ogsiveo |
| Beone Medicines USA, INC. | $15.27 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.